Blueprint Medicines Corp. (NASDAQ:BPMC) shares dropped 1.4% during mid-day trading on Friday . The stock traded as low as $27.22 and last traded at $27.24, with a volume of 63,851 shares traded. The stock had previously closed at $27.62.

BPMC has been the topic of several research reports. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corp. in a research report on Tuesday, May 10th. Raymond James Financial Inc. initiated coverage on shares of Blueprint Medicines Corp. in a research report on Friday, May 27th. They set an “outperform” rating and a $23.00 price objective on the stock. Zacks Investment Research downgraded shares of Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Canaccord Genuity initiated coverage on shares of Blueprint Medicines Corp. in a research report on Friday, August 5th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, TheStreet raised shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research report on Friday, July 29th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $29.43.

The firm’s 50 day moving average is $24.21 and its 200 day moving average is $19.67. The stock’s market cap is $742.75 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last posted its earnings results on Tuesday, August 9th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.03. During the same period in the previous year, the firm posted ($0.81) earnings per share. The firm had revenue of $7.07 million for the quarter, compared to analyst estimates of $4.41 million. The company’s revenue for the quarter was up 163.0% on a year-over-year basis. On average, analysts expect that Blueprint Medicines Corp. will post ($3.05) EPS for the current year.

In related news, CEO Jeffrey W. Albers sold 17,000 shares of the company’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $22.86, for a total value of $388,620.00. Following the sale, the chief executive officer now directly owns 76,494 shares of the company’s stock, valued at $1,748,652.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.